| Zandberg, Dan P |
NCT02777385: Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer |
|
|
| Completed | 2 | 80 | US | Pembrolizumab, Keytruda, Cisplatin, Platinol, IMRT | Dan Zandberg, Merck Sharp & Dohme LLC | Head and Neck Squamous Cell Carcinoma | 04/23 | 05/23 | | |
NCT02289209: Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck |
|
|
| Active, not recruiting | 2 | 51 | US | Reirradiation, MK-3475, Keytruda, pembrolizumab | Dan Zandberg, Merck Sharp & Dohme LLC | Recurrent Head and Neck Cancer, Carcinoma, Squamous Cell of Head and Neck | 08/23 | 08/24 | | |
CA224-056, NCT04080804: Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer |
|
|
| Recruiting | 2 | 80 | US | Nivolumab, anti-PD-1 antibody, OPDIVO®, Relatlimab, anti-LAG3 antibody, BMS-986016, Ipilimumab, anti-CTLA4 antibody, Yervoy ® | Dan Zandberg, Bristol-Myers Squibb | Head and Neck Squamous Cell Carcinoma (HNSCC) | 05/26 | 09/26 | | |
NCT05743270: Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN |
|
|
| Withdrawn | 2 | 130 | Europe, US, RoW | RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel, nivolumab | Replimune Inc., Bristol-Myers Squibb | Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 03/26 | 06/26 | | |
NCT04369937: HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma |
|
|
| Active, not recruiting | 2 | 18 | US | IMRT (Intensity Modulated Radiotherapy), Pembrolizumab, Cisplatin, ISA101b, HPV-16 Vaccine | Dan Zandberg, Merck Sharp & Dohme LLC, ISA Pharmaceuticals | HPV-Related Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma | 06/25 | 06/26 | | |
NCT04326257: Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy |
|
|
| Active, not recruiting | 2 | 20 | US | Nivolumab+Relatlimab, Nivolumab: OPDIVO/ BMS-936558/ MDX1106/ ONO-4538;, Relatlimab: BMS-986016, Nivolumab+Ipilimumab, Nivolumab: OPDIVO/ BMS-936558/ MDX1106/ ONO-4538, Ipilimumab: YERVOY/ BMS-734016/ MDX-010 | Dan Zandberg, Bristol-Myers Squibb | Squamous Cell Carcinoma of the Head and Neck | 08/23 | 08/24 | | |
| Recruiting | 1/2 | 242 | US | DF9001, pembrolizumab, KEYTRUDA® | Dragonfly Therapeutics, Merck Sharp & Dohme LLC | Solid Tumor, Adult | 08/25 | 11/27 | | |
KURRENT-HN, NCT04997902: Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) |
|
|
| Recruiting | 1/2 | 40 | US | Tipifarnib, Alpelisib, BYL719 | Kura Oncology, Inc. | HNSCC | 07/25 | 07/25 | | |
NCT05472506: Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer |
|
|
| Withdrawn | 1 | 54 | US | IK-175 + nivolumab | Ikena Oncology, Bristol-Myers Squibb | Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head Cancer, Neck Cancer, Head Cancer Neck, Neck Carcinoma | 04/23 | 04/23 | | |
| Marino, Brieana |
NCT04631744: Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) |
|
|
| Recruiting | 2 | 30 | US | Cabozantinib | Weill Medical College of Cornell University, Exelixis | Prostate Cancer | 07/26 | 07/27 | | |
